Clinical Trials

Aurigene Discovery Technologies Ltd, a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd and Curis, Inc. have announced plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India. This was announced following the presentation of preliminary data from the initial 34…
Novartis announced, first of its kind phase III data showing Cosentyx (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland.  …
GlaxoSmithKline plc, announced the publication of full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD). Data from the investigational clinical development programme showed that treating eosinophilic COPD patients with the biologic medicine, mepolizumab, in addition to maximal guideline-recommended therapy, reduced exacerbations in these difficult-to-treat…
ESSA Pharma Inc. , a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced that results from the Phase 1 portion of the Phase 1/2 clinical trial of EPI-506 for the treatment of metastatic castrationresistant prostate cancer (“mCRPC”) were presented at the…
Antibe Therapeutics has announced that it has received approval from Health Canada to initiate a Phase 2, double-blind, gastrointestinal endoscopy trial for its lead drug ATB-346. The study will involve a total of 240 healthy volunteers, who will be randomised to one of two groups. One group will be treated…
Page 1 of 26

Subscribe To Our Newsletter

Security Q:How many eyes has a typical person? (ex: 1)
Name:
Email: